Hangzhou Conlead, founded by Leadingpharm and Huluwa, has been focusing on the research and development of high-end pediatric formulations since its inception in 2022, shouldering the mission of solving medication problems for children and the elderly. Over the past two years, this young pharmaceutical research and development enterprise has gradually emerged with continuous technological innovation and strong research and development capabilities, committed to becoming a leading brand in the field of pediatric medicine in China.
 

Within two years, Conlead has established multiple formulation platforms, including oral films, complex particles, and special oral solutions, achieving comprehensive coverage in the fields of chemical medicine, traditional Chinese medicine and biopharmaceuticals. Its professional abilities in pharmaceutical research, in vitro and in vivo evaluation, and registration application have been widely recognized in the industry. At present, with the support and collaboration of experts and R&D teams of Leadingpharm, Conlead has formed a professional R&D team of nearly 60 people and successfully carried out the research and development of more than 30 products. Among them, nearly 10 products have obtained clinical implied licenses, and 12 patents have been independently developed and applied for.

Looking ahead to the future, Conlead will rely on its strong research and development capabilities and rich industry experience to strive to develop innovative drugs that can fill market gaps, provide customers with one-stop research and development services, and thus create new productivity. This new type of productivity will not only promote the high-quality development of Conlead itself, but also inject new vitality and momentum into the entire biopharmaceutical industry.
 

-END-